 |
1 Product |  |
13 Diseases | | 1 Product |
|
0 Trials |  |
20 News |  |
- Cvac (cancer vaccine MUC-1) / Sydys Corp
Enrollment change: Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment (clinicaltrials.gov) - Dec 14, 2016
P2, N=91, Terminated, Sponsor: Prima BioMed Ltd
N=132 --> 91
- |||| Cvac (cancer vaccine MUC-1) / Sydys Corp
Trial completion: Ovarian Cancer Vaccine for Patients in Remission (clinicaltrials.gov) - May 27, 2015
P2b, N=63, Completed, Sponsor: Prima BioMed Ltd
N=132 --> 91 Active, not recruiting --> Completed
- | Cvac (cancer vaccine MUC-1) / Sydys Corp
Trial termination: Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment (clinicaltrials.gov) - Apr 14, 2015
P2, N=132, Terminated, Sponsor: Prima BioMed Ltd
Active, not recruiting --> Completed Recruiting --> Terminated; The study was terminated due to company restructuring and changes in drug development priorities.
- Cvac (cancer vaccine MUC-1) / Sydys Corp
Enrollment change, Trial withdrawal, Trial primary completion date: Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas (clinicaltrials.gov) - Apr 14, 2015
P2, N=0, Withdrawn, Sponsor: Prima BioMed Ltd
Recruiting --> Terminated; The study was terminated due to company restructuring and changes in drug development priorities. N=40 --> 0 | Terminated --> Withdrawn | Trial primary completion date: Feb 2019 --> Mar 2015
- Cvac (cancer vaccine MUC-1) / Sydys Corp
Enrollment change, Trial primary completion date: Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment (clinicaltrials.gov) - Apr 3, 2015
P2, N=132, Terminated, Sponsor: Prima BioMed Ltd
N=40 --> 0 | Terminated --> Withdrawn | Trial primary completion date: Feb 2019 --> Mar 2015 N=286 --> 132 | Trial primary completion date: Jul 2015 --> Feb 2015
- | Cvac (cancer vaccine MUC-1) / Sydys Corp
Enrollment open, Trial primary completion date: Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas (clinicaltrials.gov) - Feb 19, 2015
P2, N=40, Recruiting, Sponsor: Prima BioMed Ltd
N=286 --> 132 | Trial primary completion date: Jul 2015 --> Feb 2015 Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2018 --> Feb 2019
- | Cvac (cancer vaccine MUC-1) / Sydys Corp
New P2 trial: Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas (clinicaltrials.gov) - Dec 8, 2014
P2, N=40, Not yet recruiting, Sponsor: Prima BioMed Ltd
- || Cvac (cancer vaccine MUC-1) / Sydys Corp
Trial primary completion date: Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment (clinicaltrials.gov) - Jul 2, 2014
P2, N=286, Recruiting, Sponsor: Prima BioMed Ltd
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2018 --> Feb 2019 Trial primary completion date: Dec 2016 --> Jul 2015
- |||| Cvac (cancer vaccine MUC-1) / Sydys Corp
Enrollment open, Trial primary completion date: Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment (clinicaltrials.gov) - Jun 29, 2014
P2, N=350, Recruiting, Sponsor: Prima BioMed Ltd
Trial primary completion date: Dec 2016 --> Jul 2015 Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2016 --> Jul 2015
- Cvac (cancer vaccine MUC-1) / Sydys Corp
Trial primary completion date: Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study (clinicaltrials.gov) - Jun 19, 2014
P2, N=9, Completed, Sponsor: Prima BioMed Ltd
Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2016 --> Jul 2015 Trial primary completion date: Dec 2013 --> Apr 2014
- Cvac (cancer vaccine MUC-1) / Sydys Corp
Trial completion, Trial primary completion date: Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study (clinicaltrials.gov) - Jun 19, 2014
P2, N=9, Completed, Sponsor: Prima BioMed Ltd
Trial primary completion date: Dec 2013 --> Apr 2014 Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Apr 2014
- ||| Cvac (cancer vaccine MUC-1) / Sydys Corp
Enrollment closed: Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment (clinicaltrials.gov) - Jun 19, 2014
P2, N=350, Active, not recruiting, Sponsor: Prima BioMed Ltd
Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Apr 2014 Recruiting --> Active, not recruiting
- ||| Cvac (cancer vaccine MUC-1) / Sydys Corp
Enrollment change: Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment (clinicaltrials.gov) - Feb 4, 2014
P2, N=350, Recruiting, Sponsor: Prima BioMed Ltd
Recruiting --> Active, not recruiting N=1000 --> 350
- Cvac (cancer vaccine MUC-1) / Sydys Corp
Enrollment closed: Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study (clinicaltrials.gov) - Jan 13, 2013
P2, N=9, Active, not recruiting, Sponsor: Prima BioMed Ltd
N=1000 --> 350 Enrolling by invitation --> Active, not recruiting
- Cvac (cancer vaccine MUC-1) / Sydys Corp
Trial initiation date: Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study (clinicaltrials.gov) - Dec 20, 2012
P2, N=9, Active, not recruiting, Sponsor: Prima BioMed Ltd
Enrolling by invitation --> Active, not recruiting Initiation date: Apr 2011 --> Dec 2011
- Cvac (cancer vaccine MUC-1) / Sydys Corp
Enrollment change: Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study (clinicaltrials.gov) - Dec 20, 2012
P2, N=9, Active, not recruiting, Sponsor: Prima BioMed Ltd
Initiation date: Apr 2011 --> Dec 2011 N=15 --> 9
- ||| Cvac (cancer vaccine MUC-1) / Sydys Corp
Trial initiation date: Ovarian Cancer Vaccine for Patients in Remission (clinicaltrials.gov) - Dec 20, 2012
P2b, N=63, Active, not recruiting, Sponsor: Prima BioMed Ltd
N=15 --> 9 Initiation date: Feb 2010 --> Jun 2010
- Cvac (cancer vaccine MUC-1) / Sydys Corp
New P2 trial: Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study (clinicaltrials.gov) - Jun 10, 2012
P2, N=9, Active, not recruiting, Sponsor: Prima BioMed Ltd
- ||||| Cvac (cancer vaccine MUC-1) / Sydys Corp
New P2 trial: Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment (clinicaltrials.gov) - Jan 26, 2012
P2, N=350, Recruiting, Sponsor: Prima BioMed Ltd
- ||| Cvac (cancer vaccine MUC-1) / Sydys Corp
Enrollment closed: Ovarian Cancer Vaccine for Patients in Remission (clinicaltrials.gov) - Sep 18, 2011
P2b, N=63, Active, not recruiting, Sponsor: Prima BioMed Ltd
Initiation date: Feb 2010 --> Jun 2010 Recruiting --> Active, not recruiting